Principal Financial Group Inc. Trims Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

Principal Financial Group Inc. lowered its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 69.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 12,513 shares of the company’s stock after selling 28,706 shares during the period. Principal Financial Group Inc.’s holdings in ImmunityBio were worth $47,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of ImmunityBio during the 3rd quarter valued at $51,000. Barclays PLC lifted its position in shares of ImmunityBio by 127.4% in the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock valued at $1,344,000 after acquiring an additional 202,248 shares in the last quarter. XTX Topco Ltd lifted its position in shares of ImmunityBio by 309.4% in the third quarter. XTX Topco Ltd now owns 92,910 shares of the company’s stock valued at $346,000 after acquiring an additional 70,215 shares in the last quarter. State Street Corp grew its position in shares of ImmunityBio by 10.1% during the third quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after purchasing an additional 790,408 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in shares of ImmunityBio during the third quarter worth about $136,000. 8.58% of the stock is currently owned by institutional investors.

ImmunityBio Trading Down 1.1 %

Shares of IBRX stock opened at $2.73 on Wednesday. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -2.97 and a beta of 0.86. ImmunityBio, Inc. has a 12-month low of $2.50 and a 12-month high of $10.53. The stock’s 50-day moving average price is $4.13 and its 200-day moving average price is $4.43.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IBRX. D. Boral Capital restated a “buy” rating and issued a $30.00 price target on shares of ImmunityBio in a research note on Monday. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.